Table 3. Crude and adjusted analyses for the association between type of comorbidity, and the overall and disease-specific mortality in patients with localized and metastatic disease respectively (n = 2167).

		Overall mortality				Disease-specific mortality
				HR (95% CI)				HR (95% CI)
	N	1-year (%)	5-year (%)	Crude	Adjusted*	1-year (%)	5-year (%)	Crude	Adjusted*
Total	2167
Localized
Overall	1906	8	32			6	23
No comorbidity	1553	7	29	1	1	4	20	1	1
Cardiopulmonary	54	13	39	1.48 (0.97–2.25)	1.21 (0.80–1.84)	6	26	1.52 (0.91–2.55)	1.36 (0.81–2.28)
Gastrointestinal	16	31	68	3.14 (1.72–5.70)	1.86 (1.02–3.40)	13	34	2.11 (0.87–2.07)	1.64 (0.67–3.98)
Neurovascular	18	13	49	1.99 (1.31–3.02)	1.33 (0.87–2.02)	6	20	1.02 (0.51–2.07)	0.84 (0.41–1.70)
Malignant neoplasm	154	16	45	1.83 (1.44–2.34)	1.41 (1.10–1.80)	13	31	1.90 (1.41–2.57)	1.66 (1.22–2.25)
Miscellaneous**	81	14	48	2.85 (1.50–2.81)	1.48 (1.07–2.03)	11	31	1.78 (1.17–2.69)	1.51 (0.99–2.30)
Metastatic
Overall	261	50	83			48	81
No comorbidity	188	47	84	1	1	45	78	1	1
Cardiopulmonary	6	50	-	0.84 (0.31–2.26)	0.69 (0.25–1.86)	50	71	0.91 (0.34–2.46)	0.75 (0.27–2.03)
Gastrointestinal	2	50	-	1.16 (0.29–4.69)	0.76 (0.18–3.26)	-	60	0.63 (0.09–4.53)	0.43 (0.06–3.20)
Neurovascular	9	78	78	1.61 (0.76–3.45)	1.23 (0.57–2.66)	67	66	1.50 (0.66–3.40)	1.15 (0.50–2.64)
Malignant neoplasm	42	60	79	1.01 (0.70–1.47)	0.82 (0.56–1.22)	57	76	1.07 (0.73–1.56)	0.87 (0.59–1.30)
Miscellaneous**	14	43	-	1.02 (0.57–1.84)	0.91 (0.51–1.65)	43	80	1.01 (0.55–1.86)	0.90 (0.49–1.67)

CI: confidence interval; HR: hazard ratio; N: number.

* Analyses adjusted for age.

** Diabetes with or without end organ damage, connective tissue disease, and moderate/severe renal disease